|
Good website:
http://www.geocities.com/CapeCanaveral/Lab/3608/Plotkin.htmlPlotkin H, Rauch F, Lanoue G, Travers R, Glorieux FH. Severe
osteogenesis
imperfecta: effect of one year of pamidronate (APD)
treatment in children under two years of age. Bone 1998; 23:s192.
http://content.nejm.org/cgi/content/abstract/339/14/947?ijkey=eab2b1a400bfae9857236f649626d31a03e7900a&keytype2=
tf_ipsecsha
Glorieux
F, Bishop N, Plotkin H, Chabot G, Lanoue G, Travers R.
Cyclical Pamidronate Therapy in Children with Severe Osteogenesis
Imperfecta.
N Engl J Med 1998; 339:947-952.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9510450 (abstract
available)
Astrom
E, Soderhall S. Beneficial effect of bisphosphonate during
five years of treatment of severe osteogenesis imperfecta. Acta
Paediatr.
1998 Jan;87(1):64-8.
http://jcem.endojournals.org/cgi/content/abstract/85/5/1846?ijkey=f95494babb73c80c770595bcc99a847be8a9becb&keytype2=
tf_ipsecsha
Glorieux
FH. Bisphosphonate therapy for severe osteogenesis
imperfecta. J Pediatr Endocrinol Metab. 2000 Sep;13 Suppl 2:989-92.
http://jcem.endojournals.org/cgi/content/full/85/5/1846 (free article
available online)
Plotkin H, Rauch F, Bishop NJ, Montpetit K,
Ruck-Gibis J, Travers R,
Glorieux FH. Pamidronate treatment of severe osteogenesis imperfecta
in children under 3 years
of age. J Clin Endocrinol Metab. 2000
May;85(5):1846-50.
http://adc.bmjjournals.com/cgi/content/full/87/6/562-a (free
article available online)
I Banerjee1, G J Shortland1, W D Evans1 and
J W Gregory2 Osteogenesis
imperfecta and intravenous pamidronate
Archives of Disease in Childhood 2002;87:562-563
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12457260 (abstract
available)
Shapiro
JR, McCarthy EF, Rossiter K, Ernest K, Gelman R, Fedarko N,
Santiago HT, Bober M The effect of intravenous pamidronate
on bone
mineral density, bone histomorphometry, and parameters of bone
turnover in adults with type IA osteogenesis
imperfecta.
Calcif Tissue Int. 2003 Feb;72(2):103-12. Epub 2002 Dec 04.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12477233 (abstract
available)
Giraud
F, Meunier PJ. Rheumatology Department, Pavillon F, Hjpital
Edouard Heriot, Lyon Cedex 03, France.
Effect of cyclical
intravenous pamidronate therapy in children with
osteogenesis imperfecta. Open-label study in seven patients.
Joint
Bone Spine. 2002 Oct;69(5):486-90.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=151622(free article available online)
Robert Lindsay Modeling the benefits of
pamidronate in children
with osteogenesis imperfecta J Clin Invest. 2002 November 1; 110
(9): 1239–1241
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=12417568 (free article available online)
Rauch
F, Travers R, Plotkin H, Glorieux FH. The effects of
intravenous pamidronate on the bone tissue of children and
adolescents
with osteogenesis imperfecta. J Clin Invest. 2002
Nov;110(9):1293-9.
http://adc.bmjjournals.com/cgi/content/full/86/5/356 (free article
available online)
Archives of Disease in Childhood 2002;86:356-364
E Åström1 and S
Söderhäll2 Beneficial effect of long term intravenous
bisphosphonate treatment of osteogenesis imperfecta
http://jcem.endojournals.org/cgi/content/full/88/3/986 (free
article available online)
F. Rauch, H. Plotkin, R. Travers, L. Zeitlin,
and F. H. Glorieux
Osteogenesis Imperfecta Types I, III, and IV: Effect of Pamidronate
Therapy on Bone and Mineral Metabolism
J. Clin. Endocrinol. Metab.,
March 1, 2003; 88(3): 986 - 992.
http://pediatrics.aappublications.org/cgi/content/full/111/3/573(free article available online)
Marni J. Falk, MD*, , Shauna Heeger, MS*,
Katherine A. Lynch, MS*,
Kathleen R. DeCaro, RN , Deborah Bohach, OTR/L|, Karen S. Gibson, RT¶
and Matthew L. Warman,
MD*,
Intravenous
Bisphosphonate Therapy in Children With Osteogenesis Imperfecta
PEDIATRICS Vol. 111 No. 3 March 2003,
pp. 573-578
http://www.jbmr-online.com/fulltext/01804/06100/JBMR0180406100.html (free article
available
online)
Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and
density in children and adolescents with
osteogenesis imperfecta:
effect of intravenous pamidronate therapy. J Bone Miner Res. 2003
Apr;18(4):610-4.
http://pediatrics.aappublications.org/cgi/content/full/111/5/1030(free article available online)
Leonid Zeitlin, MD, Frank Rauch, MD, Horacio
Plotkin, MD and Francis
H. Glorieux, MD, PhD Height and Weight Development During Four Years
of Therapy With Cyclical
Intravenous Pamidronate in Children and
Adolescents With Osteogenesis Imperfecta Types I, III, and IV
PEDIATRICS
Vol. 111 No. 5 May 2003, pp. 1030-1036
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15110498 (abstract
available)
Rauch
F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004 Apr
24;363(9418):1377-85.
F. Rauch Bisphosphonate
Therapy in Children With Osteogenesis
Imperfecta IBMS BoneKEy, May 1, 2004; 1(5): 5 - 8.
**********************************************************************
*****************************************************
Chapurlat
RD, Delmas PD, Liens D, Meunier PJ. Long-term effects of
intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner
Res
1997; 12:1746-52.
Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C.
Radiological manifestations of
bisphosphonate treatment with APD in a
child suffering from osteogenesis imperfecta. Skeletal Radiol 1987;
16:360-3.
Huaux
JP, Lokietek W. Is APD a promising drug in the treatment of
severe osteogenesis imperfecta? J Pediatr Orthop 1988; 8:71-2.
|
